| Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma J Zhao, AX Chen, RD Gartrell, AM Silverman, L Aparicio, T Chu, ... Nature medicine 25 (3), 462-469, 2019 | 774 | 2019 |
| An overview of meningiomas RA Buerki, CM Horbinski, T Kruser, PM Horowitz, CD James, RV Lukas Future oncology 14 (21), 2161-2177, 2018 | 570 | 2018 |
| Epidermal growth factor receptor–mediated signal transduction in the development and therapy of gliomas MK Nicholas, RV Lukas, NF Jafri, L Faoro, R Salgia Clinical Cancer Research 12 (24), 7261-7270, 2006 | 252 | 2006 |
| Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial EA Chiocca, JS Yu, RV Lukas, IH Solomon, KL Ligon, H Nakashima, ... Science translational medicine 11 (505), eaaw5680, 2019 | 244 | 2019 |
| A first-in-human phase 0 clinical study of RNA interference–based spherical nucleic acids in patients with recurrent glioblastoma P Kumthekar, CH Ko, T Paunesku, K Dixit, AM Sonabend, O Bloch, M Tate, ... Science translational medicine 13 (584), eabb3945, 2021 | 237 | 2021 |
| IDO1 inhibition synergizes with radiation and PD-1 blockade to durably increase survival against advanced glioblastoma E Ladomersky, L Zhai, A Lenzen, KL Lauing, J Qian, DM Scholtens, ... Clinical cancer research 24 (11), 2559-2573, 2018 | 186 | 2018 |
| Immunosuppressive IDO in cancer: mechanisms of action, animal models, and targeting strategies L Zhai, A Bell, E Ladomersky, KL Lauing, L Bollu, JA Sosman, B Zhang, ... Frontiers in immunology 11, 1185, 2020 | 177 | 2020 |
| Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: exploratory analyses of the phase III OAK study SM Gadgeel, RV Lukas, J Goldschmidt, P Conkling, K Park, D Cortinovis, ... Lung cancer 128, 105-112, 2019 | 172 | 2019 |
| Newly diagnosed glioblastoma: a review on clinical management RV Lukas, DA Wainwright, E Ladomersky, S Sachdev, AM Sonabend, ... Oncology (Williston Park, NY) 33 (3), 91, 2019 | 156 | 2019 |
| Rindopepimut with bevacizumab for patients with relapsed EGFRvIII-expressing glioblastoma (ReACT): results of a double-blind randomized phase II trial DA Reardon, A Desjardins, JJ Vredenburgh, DM O'Rourke, DD Tran, ... Clinical Cancer Research 26 (7), 1586-1594, 2020 | 152 | 2020 |
| Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma RV Lukas, J Rodon, K Becker, ET Wong, K Shih, M Touat, M Fassò, ... Journal of neuro-oncology 140, 317-328, 2018 | 147 | 2018 |
| Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial J Fares, AU Ahmed, IV Ulasov, AM Sonabend, J Miska, C Lee-Chang, ... The Lancet Oncology 22 (8), 1103-1114, 2021 | 146 | 2021 |
| The coincidence between increasing age, immunosuppression, and the incidence of patients with glioblastoma E Ladomersky, DM Scholtens, M Kocherginsky, EA Hibler, ET Bartom, ... Frontiers in pharmacology 10, 200, 2019 | 138 | 2019 |
| Anti-N-methyl-D-aspartate-receptor encephalitis: diagnosis, optimal management, and challenges AP Mann, E Grebenciucova, RV Lukas Therapeutics and clinical risk management, 517-525, 2014 | 132 | 2014 |
| Repeated blood–brain barrier opening with an implantable ultrasound device for delivery of albumin-bound paclitaxel in patients with recurrent glioblastoma: a phase 1 trial AM Sonabend, A Gould, C Amidei, R Ward, KA Schmidt, DY Zhang, ... The Lancet Oncology 24 (5), 509-522, 2023 | 128 | 2023 |
| ReACT: Overall survival from a randomized phase II study of rindopepimut (CDX-110) plus bevacizumab in relapsed glioblastoma. DA Reardon, J Schuster, DD Tran, KL Fink, LB Nabors, G Li, DA Bota, ... Journal of Clinical Oncology 33 (15_suppl), 2009-2009, 2015 | 124* | 2015 |
| Antiglutamic acid decarboxylase 65 (GAD65) antibody-associated epilepsy A Daif, RV Lukas, NP Issa, A Javed, S VanHaerents, AT Reder, JX Tao, ... Epilepsy & Behavior 80, 331-336, 2018 | 114 | 2018 |
| Pleomorphic xanthoastrocytoma: a brief review N Shaikh, N Brahmbhatt, TJ Kruser, KL Kam, CL Appin, NR Wadhwani, ... CNS oncology 8 (3), CNS39, 2019 | 98 | 2019 |
| Extensive brainstem infiltration, not mass effect, is a common feature of end-stage cerebral glioblastomas MR Drumm, KS Dixit, S Grimm, P Kumthekar, RV Lukas, JJ Raizer, ... Neuro-oncology 22 (4), 470-479, 2020 | 96 | 2020 |
| Advanced age increases immunosuppression in the brain and decreases immunotherapeutic efficacy in subjects with glioblastoma E Ladomersky, L Zhai, KL Lauing, A Bell, J Xu, M Kocherginsky, B Zhang, ... Clinical Cancer Research 26 (19), 5232-5245, 2020 | 91 | 2020 |
Steven J Chmura MD, PhDUniversity of ChicagoCorreu electrònic verificat a radonc.uchicago.edu
